Biogen/Eisai Win On Aduhelm Approval Bet And Wager Next On Price

 
• By Jessica Merrill

The first disease modifying drug for Alzheimer's disease will be priced at a $56,000 a year for an average weight patient, setting the drug up to be a mega blockbuster if Biogen can get it reimbursed.

betting
Biogen's big bet on aducanumab made it across the finish line • Source: Alamy

More from New Products

More from Scrip